BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 17/06/2011

FDA Releases Draft Guidance on Clinical Trial Endpoints for Non-Small Cell Lung Cancer Drugs and Biologics

The FDA has made available a draft guidance document that outlines recommended endpoints for clinical trials of non-small cell lung cancer drugs and biologics, aiming to streamline the development process and enhance the quality of submitted protocols.

Source: Federal Register — Health and Human ServicesOpen original release →